Showing 241-250 of 10484 results for "".
How Does Consideration of the Microbiome Affect Topical Product Selection
https://practicaldermatology.com/topics/atopic-dermatitis/how-does-consideration-of-the-microbiome-affect-topical-product-selection/19827/A healthy microbiome is a hallmark of healthy skin, while dysbiosis is implicated in various dermatologic diseases. Dr. Friedman explains how this knowledge should influence topical skin care.Systemic Treatment for Skin Cancers
https://practicaldermatology.com/topics/skin-cancer-photoprotection/systemic-treatment-for-skin-cancers/19662/Anisha B. Patel, MD discusses the latest advances in systemic treatment for melanoma with host Joshua Zeichner, MD. She reviews how treatments work, the most common cutaneous reactions patients experience, and the dermatologist's role in managing those reactions and reassuring patients that these reTreating Moderate to Severe Psoriasis: Weighing the Treatment Options
https://practicaldermatology.com/topics/psoriasis/-treating-moderate-to-severe-psoriasis-weighing-the-treatment-options/18375/In part 2 of her interview with DermTube Journal Club host Joshua Zeichner, MD, Erin Boh, MD reviews new biologics that provide patients with moderate to severe psoriasis improved treatment options. She discusses their efficacy and safety and offers tips for finding the right one for each patient baJanssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeNew Thinking: Eczema as a Systemic Disease
https://practicaldermatology.com/topics/psoriasis/new-thinking-eczema-as-a-systemic-disease/18756/By Seemal R. Desai, MD and Emma Guttman, MD, PhD, FAADEczema is an immune-driven disease like psoriasis. How is that knowledge changing the way that dermatologists treat patients? Are similar changes taking place for other inflammatory diseases? Dr. Guttman talks about the latest.Taylor Made: One-of-a-kind Solutions for Device-based Services
https://practicaldermatology.com/topics/practice-management/taylor-made-one-of-a-kind-solutions-for-device-based-services/18789/An expert on the leading edge of device-based interventions, Mark B. Taylor, MD has learned when and how to adopt technologies and how to get the most from the systems in his practice. In this edition of Best Practices in Aesthetics, host Joel L. Cohen, MD asks Dr. Taylor to share his tips for optimTransgender Inclusion in Dermatology: Creating a Welcoming, Safe, Affirming Practice for All
https://practicaldermatology.com/series/the-practical-dermatology-podcast/transgender-inclusion-in-dermatology-creating-a-welcoming-safe-affirming-practice-for-all/18197/Klint Peebles, MD, a Washington, DC board-certified dermatologist with expertise in working with sexual and gender-diverse patients, discusses steps that can be taken to make patients more comfortable in healthcare settings.SCALE 2024: Dr. Hilary Baldwin’s Tips and Tricks for Treating Keloids
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-hilary-baldwins-tips-and-tricks-for-treating-keloids/26366/Hilary E. Baldwin, MD, discusses best practices for the treatment of keloids at Music City SCALE.DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility study